[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003
Management of Drug and Alcohol Withdrawal
NEJM 348:1786-1795, Kosten,T.R. &O'Connor,P.G., 2003
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Validation of Diagnositc Magnetic Resonance Imaging Criteria for Multiple Sclerosis and Response to Interferon B1a
Ann Neurol 53:718-724, Barkhof,F.,et al, 2003
Risk of Ischemic Stroke Among Users of the Oral Contraceptive Pill
Stroke 34:1575-1580, Siritho,S.,et al, 2003
Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Response to Sumatriptan in Headache of MELAS Syndrome
Neurol 61:577-578, Iizuka,T.,et al, 2003
Oral Contraceptives Reduce Lamotrigine Plasma Levels
Neurol 61:570-571, Sabers,A.,et al, 2003
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Clinical Importance of Neutralising Antibodies Against Interferon Beta in Patients with Relapsing-Remitting Multiple Sclerosis
Lancet 362:1184-1191, Sorensen,P.S.,et al, 2003
Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
NEJM 349:2023-2033, Colao,A.,et al, 2003
A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease
Arch Neurol 60:1721-1728, The Parkinson Study Group, 2003
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Interferon Beta-1a for Early Multiple Sclerosis: CHAMPS Trial Subgroup Analyses
Ann Neurol 51:481-490, Beck,R.W.,et al, 2002
SUNCT Syndrome in Two Patient with Prolactinomas and Bromocriptine-Induced Attacks
Neurol 58:1698-1699, Massiou,H.,et al, 2002
Interferon Beta but not Glatiramer Acetate Therapy Aggravates Headaches in MS
Neurol 59:636-639, Pollmann,W.,et al, 2002
Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002
A Randomized, Double-Blind, Dose-Comparison Study of Weekly Interferon B-1a in Relapsing MS
Neurol 59:1507-1517,1482, Clanet,M.,et al, 2002
Randomized, Comparative Study of Interferon B-1a Treatment Regimens in MS
Neurol 59:1496-1506,1482, Panitch,H.,et al, 2002
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease
JAMA 287:455-463,509, Hobson,D.E.,et al, 2002
An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Cerebral Vasoconstriction and Stroke After Use of Serotonergic Drugs
Neurol 58:130-133, Singhal,A.B.,et al, 2002
Almotriptan (AXERT) and Frovatriptan (FROVA) for Migraine
The Medical Letter 44:19-20, , 2002
The Safety of Triptans in the Treatment of Patients with Migraine
Am J Med 112:135-140, Jamieson,D.G., 2002
Alopecia Induced by Dopamine Agonists
Neurol 58:829-830, Tabamo,R.E. &Di Rocco,A., 2002
Treatment of Women with Epilepsy
Seminars in Neurology 22:289-297, Pack.A.M.&Morrell,M.J., 2002
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
Oral Triptans (serotonin 5-HT 1B/1D agnosists) in Acute Migraine Treatment: A Meta-analysis of 53 Trials
Lancet 358:1668-1675, Ferrari,M.D.,et al, 2001
The Effect of IFNB-1b on the Evolution of Enhancing Lesions in Secondary Progressive MS
Neurol 57:2185-2190, Brex,P.A.,et al, 2001
What Matters is Not the Differences Between Triptans, but the Differences Between Patients
Arch Neurol 58:1481-1482, Saper,J.R., 2001
Triptans Are All Different
Arch Neurol 58:1479-1480,1482, Rapoport,A.M.&Tepper,S.J., 2001
A randomized,Double-blind,Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events
Arch Neurol 58:1385-1392, Dewey,R.B.,et al, 2001
Evaluation of CSf-tau and CSF-AB42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Arch Neurol 58:373-379,349, Andreasen,N.,et al, 2001
Intracranial Hemorrhages Associated with Sumatriptan
Neurol 56:1243-1244, Combremont,P.C. & Marcus,E.M., 2001
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
Fulminant Liver Failure During Interferon Beta Treatment of Multiple Sclerosis
Neurol 56:1416, Yoshida,E.M.,et al, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1496-1504, Secondary Progressive Efficacy Clinical Trial of R, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1505-1513, Li,D.K.B.,et al, 2001
Third Generation Oral Contraceptives and Risk of Venous Thrombosis: Meta-Analysis
BMJ 323:131-134, Kemmermen,J.M.,et al, 2001
PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Safety of Pramipexole in Patients with Restless Legs Syndrome
Neurol 55:1589-1590, Stiasny,K.,et al, 2000
Triptans and Migraine
Lancet 355:860-861, Bateman,D.N., 2000
Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000